Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Buse

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Diabetes, Obesity & Metabolism|October 18, 2014
Is insulin the most effective injectable antihyperglycaemic therapy?J B Buse, A Peters, D Russell-Jones, et al.
The American Journal of Physiology|March 1, 1992
Human intestinal glucose transporter expression and localization of GLUT5N O Davidson, A M Hausman, C A Ifkovits, et al.
Diabetes, Obesity & Metabolism|March 3, 2015
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trialsR R Henry, J B Buse, H Wu, et al.
Diabetologia|July 1, 1984
Class I, II and III major histocompatibility complex gene polymorphisms in BB ratsJ B Buse, D D Chaplin, A Ben-Nun, et al.
The Journal of Experimental Medicine|June 1, 1984
Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrossesR A Jackson, J B Buse, R Rifai, et al.
Nucleic Acids Research|August 11, 1991
Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCPA Muraoka, H Sakura, K Kim, et al.
The Journal of Clinical Investigation|February 1, 1994
Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytesC F Burant, S Flink, A M DePaoli, et al.
Diabetes, Obesity & Metabolism|May 19, 2015
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialS C L Gough, B W Bode, V C Woo, et al.
Science (New York, N.Y.)|February 14, 1986
The NOD mouse: recessive diabetogenic gene in the major histocompatibility complexM Hattori, J B Buse, R A Jackson, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trialsS R K Seshasai, R L Bennett, J R Petrie, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Diabetes, Obesity & Metabolism|October 18, 2014
Is insulin the most effective injectable antihyperglycaemic therapy?J B Buse, A Peters, D Russell-Jones, et al.
The American Journal of Physiology|March 1, 1992
Human intestinal glucose transporter expression and localization of GLUT5N O Davidson, A M Hausman, C A Ifkovits, et al.
Diabetes, Obesity & Metabolism|March 3, 2015
Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trialsR R Henry, J B Buse, H Wu, et al.
Diabetologia|July 1, 1984
Class I, II and III major histocompatibility complex gene polymorphisms in BB ratsJ B Buse, D D Chaplin, A Ben-Nun, et al.
The Journal of Experimental Medicine|June 1, 1984
Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrossesR A Jackson, J B Buse, R Rifai, et al.
Nucleic Acids Research|August 11, 1991
Polymorphism in exon 4a of the human GLUT4/ muscle-fat facilitative glucose transporter gene detected by SSCPA Muraoka, H Sakura, K Kim, et al.
The Journal of Clinical Investigation|February 1, 1994
Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytesC F Burant, S Flink, A M DePaoli, et al.
Diabetes, Obesity & Metabolism|May 19, 2015
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialS C L Gough, B W Bode, V C Woo, et al.
Science (New York, N.Y.)|February 14, 1986
The NOD mouse: recessive diabetogenic gene in the major histocompatibility complexM Hattori, J B Buse, R A Jackson, et al.
Diabetes, Obesity & Metabolism|February 7, 2015
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trialsS R K Seshasai, R L Bennett, J R Petrie, et al.
Pageof 5